Creo Medical Group PLC (AIM:CREO)
London · Delayed Price · Currency is GBP · Price in GBX 13.99
+0.24 (1.78%)
Jul 28, 2026, 8:34 AM GMT
Creo Medical Group Balance Sheet
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 12.4 | 8.7 | 3 | 13.1 | 43.53 |
Short-Term Investments | - | - | 15.5 | - | - |
Cash & Short-Term Investments | 12.4 | 8.7 | 18.5 | 13.1 | 43.53 |
Cash Growth | 42.53% | -52.97% | 41.22% | -69.91% | -3.45% |
Accounts Receivable | 5.6 | 2 | 8.6 | 6.8 | 4.83 |
Total Trade Receivables | 5.6 | 2 | 8.6 | 6.8 | 4.83 |
Inventory | 2.5 | 2.7 | 8.1 | 9.3 | 8.5 |
Other Current Assets | 3 | 43 | 2.7 | 4.5 | 4.3 |
Total Current Assets | 23.5 | 56.4 | 37.9 | 33.7 | 61.17 |
Net Property, Plant & Equipment | 3.4 | 5.9 | 9.1 | 10.2 | 8.6 |
Other Intangible Assets | 1.3 | 0.5 | 7.1 | 8 | 8.69 |
Goodwill | - | - | 19.1 | 19.6 | 18.56 |
Long-Term Investments | 30.9 | 2.1 | 2.1 | 2.1 | 1.73 |
Other Long-Term Assets | - | 0.1 | 1.3 | 1.7 | 1.85 |
Total Assets | 59.1 | 65 | 76.6 | 75.2 | 100.61 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.9 | 3.9 | 5.7 | 9 | 9.92 |
Short-Term Debt | - | - | - | 1.6 | 1.68 |
Current Portion of Long-Term Debt | 2.3 | 2.4 | 3.1 | 4 | 3.71 |
Other Current Liabilities | 0.1 | 14.2 | 1.1 | 2.8 | 4.44 |
Total Current Liabilities | 7.3 | 20.5 | 9.9 | 17.4 | 19.74 |
Long-Term Debt | 1.8 | 2 | 5.2 | 6.1 | 5.18 |
Other Long-Term Liabilities | - | 0.1 | 1.7 | 2.4 | 2.38 |
Total Long-Term Liabilities | 1.8 | 2.1 | 6.9 | 8.5 | 7.55 |
Total Liabilities | 9.1 | 22.6 | 16.8 | 25.9 | 27.29 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.4 | 0.4 | 0.4 | 0.2 | 0.18 |
Additional Paid-in Capital | 218.5 | 217.6 | 205 | 172.4 | 170.99 |
Accumulated Other Comprehensive Income | -1.5 | -2.5 | -1.2 | -0.6 | -2.09 |
Retained Earnings | -167.4 | -173.1 | -144.4 | -122.7 | -95.76 |
Shareholders' Equity | 50 | 42.4 | 59.8 | 49.3 | 73.32 |
Total Liabilities & Equity | 59.1 | 65 | 76.6 | 75.2 | 100.61 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 4.1 | 4.4 | 8.3 | 11.7 | 10.56 |
Net Cash (Debt) | 8.3 | 4.3 | 10.2 | 1.4 | 32.98 |
Net Cash Growth | 93.02% | -57.84% | 628.57% | -95.75% | 0.74% |
Net Cash Per Share | 0.02 | 0.01 | 0.03 | 0.01 | 0.20 |
Book Value | 50 | 42.4 | 59.8 | 49.3 | 73.32 |
Book Value Per Share | 0.12 | 0.11 | 0.19 | 0.27 | 0.45 |
Tangible Book Value | 48.7 | 41.9 | 33.6 | 21.7 | 46.06 |
Tangible Book Value Per Share | 0.12 | 0.11 | 0.11 | 0.12 | 0.28 |